Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy

scientific article

Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy is …
instance of (P31):
scholarly articleQ13442814
review articleQ7318358

External links are
P356DOI10.1016/S0002-9149(97)00575-4
P698PubMed publication ID9291244

P2093author name stringR A Harrington
P2860cites workCollaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' CollaborationQ29619529
Clinical pharmacology of eptifibatideQ33500262
Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative StudyQ34247562
Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biologyQ34308581
Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplastyQ34336722
Blockade of Platelet GPIIb/IIIa Receptors as an Antithrombotic StrategyQ40430655
Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicineQ40518648
Early clinical experience with integrelin, an inhibitor of the platelet glycoprotein IIb/IIIa integrin receptorQ40966386
Antiplatelet and anticoagulant use after myocardial infarctionQ41046059
Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trialQ49173352
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.Q50994986
Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patientsQ54066813
A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary SyndromesQ56945341
Late assessment of thrombolytic efficacy (LATE) study: Prognosis in patients with non-Q wave myocardial infarctionQ56945424
Pathophysiology and management of unstable anginaQ69384213
Unstable angina. A classificationQ69664288
Aspirin, heparin, or both to treat acute unstable anginaQ70216460
Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic deathQ71306624
One-year results of the Thrombolysis in Myocardial Infarction (TIMI) IIIB clinical trial. A randomized comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q71827444
Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial IschemiaQ72344109
P433issue4A
P407language of work or nameEnglishQ1860
P921main subjectunstable anginaQ2032041
P304page(s)34B-38B
P577publication date1997-08-01
P1433published inAmerican Journal of CardiologyQ2208417
P1476titleDesign and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
P478volume80

Reverse relations

cites work (P2860)
Q61806944A Review of Antiplatelet Activity of Traditional Medicinal Herbs on Integrative Medicine Studies
Q48028091Acute coronary syndromes: 2. Antiplatelet agents
Q45937919Antiplatelet therapy. Aspirin, ticlopidine/clopidogrel, and anti-integrin agents.
Q43435430Association of the PURSUIT risk score with predischarge ejection fraction, angiographic severity of coronary artery disease, and mortality in a nonselected, community-based population with non-ST-elevation acute myocardial infarction.
Q33500262Clinical pharmacology of eptifibatide
Q28193162Clinical trials of glycoprotein IIb/IIIa inhibitors
Q28177271Clinical use of new antithrombotic therapies for medical management of acute coronary syndromes
Q33781957Development of eptifibatide
Q43571946Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study
Q33391279Eptifibatide: The evidence for its role in the management of acute coronary syndromes
Q33922853Fibrinogen receptor antagonists: design and clinical applications
Q37011736Integrin αIIbβ3: from discovery to efficacious therapeutic target
Q33635835Interventional therapy is the best approach for acute coronary syndromes
Q30305538Management of Acute Ischemic Coronary Syndromes: The Present and Future
Q34053362Management of patients with non-ST-segment elevation acute coronary syndromes: insights from the PURSUIT trial.
Q33655209New thrombolytics, anticoagulants, and platelet antagonists: the future of clinical practice
Q35663845Perspectives on the future of platelet glycoprotein IIb/IIIa blockade therapy
Q89169483Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases
Q24202522Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes
Q24202999Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes
Q24235385Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes
Q28191096Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary revascularization, and unstable angina and non-ST-segment elevation myocardial infarction
Q32076709Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy
Q45295347Recurrent ischemia during continuous 12-lead ECG-ischemia monitoring in patients with acute coronary syndromes treated with eptifibatide: relation with death and myocardial infarction. PURSUIT ECG-Ischemia Monitoring Substudy Investigators. Platelet
Q38009702Risk stratification and timing of revascularization: which patients benefit from early versus later revascularization?
Q34746674The development of interventional cardiology
Q33689211The evolving role of platelet glycoprotein IIb/IIIa inhibitors in the management of acute coronary syndromes
Q28196102Using a Systemwide Care Path to Enhance Compliance with Guidelines for Acute Myocardial Infarction